Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results

Core Insights - Interpace Biosciences reported third quarter 2025 net revenue of $8.8 million, a decrease of 29% from $12.3 million in the same quarter of 2024, but an increase of 22% from $7.3 million on a pro forma basis [5][12] - The company achieved income from continuing operations of $1.0 million, down from $1.8 million in the prior year quarter [3][5] - The third quarter marked the first full quarter as a thyroid-only diagnostics testing company, with record thyroid test volumes and revenue [2][4] Financial Performance - Q3 2025 cash collections totaled $10.0 million, compared to $11.2 million in the prior year quarter [5] - Gross profit percentage was 62%, compared to 64% in the prior year quarter [5] - Adjusted EBITDA for Q3 2025 was $1.3 million, down from $2.5 million in the prior year quarter [5][21] Operational Highlights - Thyroid test volume increased by 12% year-over-year, reaching record levels [4] - The average revenue per test increased by 5% due to reimbursement improvements [2] - The company focused on enhancing operational efficiency through AI and automation [2] Strategic Positioning - Interpace's unique combination testing platform, including ThyGeNEXT and ThyraMIRv2, supports physicians in making informed patient-management decisions [2][7] - The company is positioned as an emerging leader in personalized medicine, offering specialized services along the therapeutic value chain [6]